Literature DB >> 2660266

Protection against streptococcal pharyngeal colonization with a vaccinia: M protein recombinant.

V A Fischetti1, W M Hodges, D E Hruby.   

Abstract

Phagocytosis of group A streptococci requires type-specific antibodies directed against the variable determinants of the bacterial surface M protein molecule. As a step toward developing a broadly protective anti-streptococcal vaccine, a vaccinia virus (VV) recombinant was constructed that expresses the conserved region of the structural gene encoding the M6 molecule (VV:M6'). Mice immunized intranasally with the VV:M6' virus showed markedly reduced pharyngeal colonization by streptococci after intranasal and oral challenge with these bacteria. M protein-specific serum immunoglobulin G was significantly elevated in vaccinated animals and absent in controls. A similar approach may prove useful for the identification of protective determinants present on other bacterial and viral pathogens.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2660266     DOI: 10.1126/science.2660266

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  29 in total

1.  Surface expression of the conserved C repeat region of streptococcal M6 protein within the Pip bacteriophage receptor of Lactococcus lactis.

Authors:  B L Geller; N Wade; T D Gilberts; D E Hruby; R Johanson; L Topisirovic
Journal:  Appl Environ Microbiol       Date:  2001-12       Impact factor: 4.792

2.  Intranasal immunization with multivalent group A streptococcal vaccines protects mice against intranasal challenge infections.

Authors:  Mary A Hall; Steven D Stroop; Mary C Hu; Michael A Walls; Mark A Reddish; David S Burt; George H Lowell; James B Dale
Journal:  Infect Immun       Date:  2004-05       Impact factor: 3.441

3.  Differential effects of the streptococcal fibronectin-binding protein, FBP54, on adhesion of group A streptococci to human buccal cells and HEp-2 tissue culture cells.

Authors:  H S Courtney; J B Dale; D I Hasty
Journal:  Infect Immun       Date:  1996-07       Impact factor: 3.441

4.  Immunological relationship between the class I epitope of streptococcal M protein and myosin.

Authors:  A Quinn; K Ward; V A Fischetti; M Hemric; M W Cunningham
Journal:  Infect Immun       Date:  1998-09       Impact factor: 3.441

5.  Vaccine assembly from surface proteins of Staphylococcus aureus.

Authors:  Yukiko K Stranger-Jones; Taeok Bae; Olaf Schneewind
Journal:  Proc Natl Acad Sci U S A       Date:  2006-10-30       Impact factor: 11.205

6.  Clearance of Pseudomonas aeruginosa from the murine gastrointestinal tract is effectively mediated by O-antigen-specific circulating antibodies.

Authors:  G B Pier; G Meluleni; J B Goldberg
Journal:  Infect Immun       Date:  1995-08       Impact factor: 3.441

Review 7.  Rapid diagnosis of pharyngitis caused by group A streptococci.

Authors:  Michael A Gerber; Stanford T Shulman
Journal:  Clin Microbiol Rev       Date:  2004-07       Impact factor: 26.132

8.  Immunogenicity in mice and non-human primates of the Group A Streptococcal J8 peptide vaccine candidate conjugated to CRM197.

Authors:  Ivette Caro-Aguilar; Elizabeth Ottinger; Robert W Hepler; Deborah D Nahas; Chengwei Wu; Michael F Good; Michael Batzloff; Joseph G Joyce; Jon H Heinrichs; Julie M Skinner
Journal:  Hum Vaccin Immunother       Date:  2012-12-18       Impact factor: 3.452

9.  Priming with recombinant influenza virus followed by administration of recombinant vaccinia virus induces CD8+ T-cell-mediated protective immunity against malaria.

Authors:  S Li; M Rodrigues; D Rodriguez; J R Rodriguez; M Esteban; P Palese; R S Nussenzweig; F Zavala
Journal:  Proc Natl Acad Sci U S A       Date:  1993-06-01       Impact factor: 11.205

10.  Modulation of experimental autoimmunity: treatment of adjuvant arthritis by immunization with a recombinant vaccinia virus.

Authors:  E J Hogervorst; L Schouls; J P Wagenaar; C J Boog; W J Spaan; J D van Embden; W van Eden
Journal:  Infect Immun       Date:  1991-06       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.